Saturday 17 October 2026
Export QTTB’s income statement to Excel — free account
Q32 Bio Inc.
QTTB Healthcare Biotechnology
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.52
0.25
−3.22%
Follow QTTB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
19.68 | 4.76 | 4.26 | 4.41 | |
Current Ratio |
20.30 | 5.36 | 4.85 | 4.57 | |
Net Debt/EBITDA |
11.68 | 5.60 | 4.99 | 5.08 | |
Debt/Assets |
0.00% | 12.84% | 15.71% | 19.44% | |
Debt/Equity |
0.00 | 0.18 | 0.23 | (0.61) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.34 | 0.83 | (0.11) | 0.57 | |
Capex/Depreciation |
0.00 | 0.00 | 55.12 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.45) | (0.50) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.57 | 0.00 | |
Free Cash Flow per Share |
(0.15) | (0.45) | 0.07 | (0.35) | |
Cash per Share |
5.22 | 3.60 | 3.93 | 4.01 | |
Shareholders Equity per Share |
5.21 | 3.29 | 3.42 | (1.51) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.21 | 3.29 | 3.42 | (1.51) | |
Free Cash Flow |
(3.07) | (6.34) | 0.82 | (4.23) | |
Working Capital |
104.25 | 46.53 | 43.70 | 39.70 | |
Capital Expenditures |
— | — | 7.00 | — | |
Net Current Asset Value |
99.68 | 39.84 | 35.29 | (25.42) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | — | |
| Other line items | |||||
Average Payables |
1.24 | 1.68 | 1.93 | 1.12 | |
Average Assets |
90.99 | 71.37 | 77.05 | 81.16 | |
Average Common Equity |
46.84 | 21.15 | 23.84 | (0.08) |
Columns are period end dates